Shots: Genevant to receive up to $600M up front and milestone as well as royalties on future product sales Takeda get exclusive rights to access Genevant’s LNP technology for a specified number of selected hepatic stellate cells targets The companies collaborated to discover, develop and commercialize the LNP-delivered nucleic acid therapeutics directed to previously inaccessible […]Read More
Shots: Novartis to acquire all outstanding shares of Cadent for a total value of ~$770M. Cadent to receive $210M up front and is eligible for ~$560M as milestones. The transaction is expected to be close in Q1’21 Novartis gains full rights to Cadent’s NMDAr program which consist of two clinical programs: CAD-9303 and MIJ-821, an […]Read More
Shots: Egle has achieved the first milestone in its research agreement with Takeda, signed in June’2020. Egle will validate novel tumor-infiltrating regulatory T-cell targets while Takeda will develop the potential therapies Egle has leveraged its unique bioinformatic & translational capabilities to identify targets Following the achievement of the target identification, Egle will receive an R&D […]Read More
Shots: Evotec to receive research funding & is eligible for milestones. Evotec will support Rappta’s program of developing small molecule activators of the enzyme PP2A The collaboration leverages Evotec’s integrated platform for drug discovery and development and its oncology expertise coupled with state-of-the-art technologies PP2A is a serine/threonine phosphatase that functions as a tumor suppressor […]Read More
Shots: Schrödinger to receive $55M upfront and is eligible to receive $2.7B as preclinical, development, regulatory & commercial milestones along with royalties on sales of each product commercialized by BMS Schrödinger to grant BMS exclusive WW rights to develop & commercialize the development candidates emerges from the collaboration The collaboration will merge Schrödinger’s computational platform […]Read More
Shots: Pfizer & LianBio collaborate to focus at developing & commercializing transformative therapies in Greater China. Both the companies will leverage their clinical development, regulatory and commercial expertise Pfizer will contribute ~$70M of non-dilutive capital toward in-licensing & co-development. At LianBio’s discretion, products will be presented to Pfizer for joint development Pfizer will have a […]Read More
Shots: Silence to receive $20M up front, $10M as research milestone for SLN500 + for each of the two optioned assets, ~$663M including clinical, regulatory and commercial milestones and royalties on net sales for SLN500. Silence will also receive funds for P-I development including GMP4 manufacturing and will be responsible for all pre-clinical activities and […]Read More
Shots: Merck exercises its option to extend its Feb,2015 agreement with NGM for development and commercialization of novel biologics therapies. NGM to receive $20M as an extension fee for R&D activities during the two-year extension period in Mar 2021 & 2022 As part of the collaboration, in Jan,2019 Merck in-licensed NGM’s NASH therapy NGM313 (MK-3655), […]Read More
Shots: Alexion to acquire Syntimmune for $1.2B in cash, including an upfront payment of $400M, with additional milestone payments of up to $800M. The transaction is expected to close in Q4’18 Alexion to get the SYNT001 through this acquisition, which a humanized monoclonal antibody, which inhibits the binding of FcRn with Immunoglobulin G (IgG) and […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
